Literature DB >> 33728153

Stem Cell Therapies for Ischemic Stroke: A Systematic Review.

Abba Musa Abdullahi1, Ibrahim Muhammad Abdullahi2, Shah T Sarmast3, Arpita Bhriguvanshi4.   

Abstract

Stroke is one of the leading causes of death and disability worldwide. It is associated with a high economic burden, causing an increasing demand for highly effective, curative, and long-lasting therapies. Stem cells are unique human cells that have the capacity for developing into specialized cell types with the potential for facilitating regeneration and repair of damaged tissues. Therefore, many preclinical studies have shown the feasibility, safety, and efficacy of stem cell-based therapies; however, the evidence is still inadequate for their therapeutic use in humans. We employed a systematic approach to search published data from 2000 to 2020 on five main databases: PubMed, PubMed Central, Google Scholar, ScienceDirect, and Medline. Two research registries were also searched: the Cochrane Registry and clinicaltrial.gov. Data was collected after applying inclusion and exclusion criteria and studies were appraised critically. Both Medical Subject Headings (MeSH) and regular keyword search strategies were employed. The findings of this study are in line with previously reported studies in which stem cell-based therapies were found to be relatively safe, feasible, and effective.
Copyright © 2021, Abdullahi et al.

Entities:  

Keywords:  ischemic stroke; regeneration; repair; stem cells; therapy; transplantation

Year:  2021        PMID: 33728153      PMCID: PMC7936858          DOI: 10.7759/cureus.13139

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  33 in total

1.  Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke.

Authors:  Osamu Honmou; Kiyohiro Houkin; Takuya Matsunaga; Yoshiro Niitsu; Sumio Ishiai; Rie Onodera; Stephen G Waxman; Jeffery D Kocsis
Journal:  Brain       Date:  2011-04-14       Impact factor: 13.501

Review 2.  How to perform a critical analysis of a randomised controlled trial.

Authors:  Candice Estellat; David J Torgerson; Philippe Ravaud
Journal:  Best Pract Res Clin Rheumatol       Date:  2009-04       Impact factor: 4.098

Review 3.  Bone marrow mononuclear cell therapy in ischaemic stroke: a systematic review.

Authors:  A Kumar; M Prasad; V P Jali; A K Pandit; S Misra; P Kumar; K Chakravarty; P Kathuria; A Gulati
Journal:  Acta Neurol Scand       Date:  2016-08-24       Impact factor: 3.209

4.  A Phase 2 Randomized, Sham-Controlled Trial of Internal Carotid Artery Infusion of Autologous Bone Marrow-Derived ALD-401 Cells in Patients With Recent Stable Ischemic Stroke (RECOVER-Stroke).

Authors:  Sean I Savitz; Dileep Yavagal; George Rappard; William Likosky; Neal Rutledge; Carmelo Graffagnino; Yazan Alderazi; Jennifer A Elder; Peng R Chen; Ronald F Budzik; Ronald Tarrel; David Y Huang; James M Hinson
Journal:  Circulation       Date:  2019-01-08       Impact factor: 29.690

5.  Autologous mesenchymal stem cell transplantation in stroke patients.

Authors:  Oh Young Bang; Jin Soo Lee; Phil Hyu Lee; Gwang Lee
Journal:  Ann Neurol       Date:  2005-06       Impact factor: 10.422

6.  Granulocyte-colony stimulating factor for mobilizing bone marrow stem cells in subacute stroke: the stem cell trial of recovery enhancement after stroke 2 randomized controlled trial.

Authors:  Timothy J England; Maryam Abaei; Dorothee P Auer; James Lowe; D Rhodri E Jones; Gillian Sare; Marion Walker; Philip M W Bath
Journal:  Stroke       Date:  2011-12-22       Impact factor: 7.914

7.  Intra-Arterial Immunoselected CD34+ Stem Cells for Acute Ischemic Stroke.

Authors:  Soma Banerjee; Paul Bentley; Mohammad Hamady; Stephen Marley; John Davis; Abdul Shlebak; Joanna Nicholls; Deborah A Williamson; Steen L Jensen; Myrtle Gordon; Nagy Habib; Jeremy Chataway
Journal:  Stem Cells Transl Med       Date:  2014-08-08       Impact factor: 6.940

8.  Intravenous Autologous Bone Marrow Mononuclear Cell Transplantation for Stroke: Phase1/2a Clinical Trial in a Homogeneous Group of Stroke Patients.

Authors:  Akihiko Taguchi; Chiaki Sakai; Toshihiro Soma; Yukiko Kasahara; David M Stern; Katsufumi Kajimoto; Masafumi Ihara; Takashi Daimon; Kenichi Yamahara; Kaori Doi; Nobuo Kohara; Hiroyuki Nishimura; Tomohiro Matsuyama; Hiroaki Naritomi; Nobuyuki Sakai; Kazuyuki Nagatsuka
Journal:  Stem Cells Dev       Date:  2015-08-17       Impact factor: 3.272

9.  Trends in mesenchymal stem cell clinical trials 2004-2018: Is efficacy optimal in a narrow dose range?

Authors:  Maciej Kabat; Ivan Bobkov; Suneel Kumar; Martin Grumet
Journal:  Stem Cells Transl Med       Date:  2019-12-05       Impact factor: 6.940

10.  Allogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stroke: Clinical Outcomes from a Phase I Safety Study.

Authors:  Daniel T Laskowitz; Ellen R Bennett; Rebecca J Durham; John J Volpi; Jonathan R Wiese; Michael Frankel; Elizabeth Shpall; Jeffry M Wilson; Jesse Troy; Joanne Kurtzberg
Journal:  Stem Cells Transl Med       Date:  2018-05-12       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.